Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
ADH-1
Clinical data | |
---|---|
Trade names | Exherin |
ATC code |
|
Identifiers | |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H34N8O6S2 |
Molar mass | 570.68 g·mol−1 |
3D model (JSmol) | |
| |
|
ADH-1 (brand name Exherin) is a small, cyclic pentapeptide vascular-targeting drug. It was developed by Adherex Technologies.
ADH-1 selectively and competitively binds to and blocks N-cadherin, which may result in disruption of tumor vasculature, inhibition of tumor cell growth, and the induction of tumor cell and endothelial cell apoptosis. N-cadherin, a cell- surface transmembrane glycoprotein of the cadherin superfamily of proteins involved in calcium-mediated cell–cell adhesion and signaling mechanisms; may be upregulated in some aggressive tumors and the endothelial cells and pericytes of some tumor blood vessels.
In 2006, Adherex and NCI formed a Clinical Trial Agreement stating that NCI will sponsor clinical trials of ADH-1 in a variety of cancer types. ADH-1 received orphan drug status from the FDA in 2008.
In a pilot study (phase I trial), ADH-1 intravenous pretreatment before chemotherapy in metastatic melanoma completely destroyed tumors in half of patients. It is being investigated for advanced extremity melanoma in phase II trials.